Follicular lymphoma is essentially a disease of the elderly, and the aging of the population in developed countries will increase
patient numbers in coming years. Significant achievements have been made for treatment, but better understanding of the disease and
major progress in biology now facilitate the development of many new drugs, which may have improved toxicity profiles making them
appropriate for treatment of older adults. However, the increasing number of treatment possibilities, can also increase the toxicity risks,
and unexpected toxicities specific to older adults may be encountered. Consequently, specific studies of older patients should be
considered, using appropriate evaluation tools such as comprehensive geriatric assessment. This review will described the development
of these new drugs, in the context of the treatment of older-adults with follicular lymphoma.